The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction
- 12 September 2014
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (3) , 987-993
Abstract
Background We analyzed the role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) on the microscopic component of the disease in patients with a first recurrence of...Keywords
This publication has 34 references indexed in Scilit:
- Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancerEuropean Journal of Surgical Oncology, 2011
- Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancerCancer, 2007
- A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma PeritoneiAnnals of Surgical Oncology, 2006
- Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR TrialAnnals of Surgical Oncology, 2006
- Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinomaCancer, 2006
- Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 TrialJournal of Clinical Oncology, 2005
- The role of secondary cytoreductive surgery for recurrent ovarian cancerGynecologic Oncology, 2005
- Critical evaluation of secondary cytoreduction in recurrent ovarian cancerGynecologic Oncology, 2004
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996